Myopathic rheumatic diseases (polymyositis, dermatomyositis, inclusion body myositis)

13S137: Juvenile Myositis: Beyond Consensus Treatment

Moderator(s)

• 

  Lisa Rider, MD

  NIEHS, NIH
  Garrett Park, MD, United States

  Disclosure(s): Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Terminated, December 31, 2020); Hope Pharmaceuticals: Grant/Research Support (Ongoing)
• JT

  Jessica Turnier, MD, MS

  University of Michigan
  Saline, MI, United States

  Disclosure(s): No financial relationships to disclose

Experts in juvenile myositis will provide updates in treatment beyond standard therapies. Dr. Huber will provide a review of consensus treatment plans with a focus on biologic therapies in juvenile myositis. Dr. Kim will provide an overview of skin disease consensus management plans with updates on treatment for refractory skin disease in juvenile myositis. Dr. Kim will also review the role of JAKi treatment in juvenile myositis. You can also expect a panel Q&A, allowing the audience to interact directly with the expert panel regarding clinical treatment questions.

Presentations:

• 12:00 PM – 12:15 PM Eastern Time

  Biologic Therapies in Juvenile Myositis
  

  Speaker: Adam Huber, MD, MSc – IWK Health Centre
• 12:15 PM – 12:20 PM Eastern Time

  Q&A
  
• 12:20 PM – 12:35 PM Eastern Time

  JAK Inhibitor Treatment in Juvenile Myositis
  

  Speaker: Hanna Kim, MD, MS – NIAMS, NIH
• 12:35 PM – 12:40 PM Eastern Time

  Q&A
  
• 12:40 PM – 12:55 PM Eastern Time

  Management of Refractory Skin Disease in Juvenile Myositis
  

  Speaker: Susan Kim, MD – UCSF Benioff Children's Hospital
• 12:55 PM – 1:00 PM Eastern Time

  Q&A